Avis Budget Group, Inc. (CAR)
Avis Surges 11% as Shorts Can't Cover: Parabolic Blow-Off or Generational Squeeze?
Avis Budget Group (NASDAQ:CAR) stock is up 11% midday Monday, climbing from $493.86 to $550 as short-sellers scramble to cover positions they can no longer afford to hold.
Avis Budget: Looking Beyond The Short Squeeze
Avis Budget (CAR) stock has surged by almost 390% over the last month and rose by almost 10% in Friday's trading, driven by a powerful short squeeze.
How a ‘short squeeze' could still move Avis's stock much higher
Avis's stock could still rally a lot more because of a technical “short squeeze” triggered in late March, according to Deutsche Bank.
Fade the Rally in Avis Stock & Buy Hertz's Instead?
Car rental stocks surged on Thursday after Hertz (HTZ) reported a significant increase in website traffic as travelers look for alternatives to flying amid a TSA shortage.
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet
Lyell Immunopharma is a CAR-T developer with a single pivotal asset, ronde-cel, targeting LBCL and showing superior early efficacy and safety data. Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3L+ LBCL patients outperformed approved peers, supporting a $1B+ peak sales opportunity. Valuation estimates suggest LYEL equity value of ~$45–55 per share, with the current price reflecting moderate success probability; pivotal data in 2027 is key.
Avis Budget (CAR) Up 3.8% Since Last Earnings Report: Can It Continue?
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value
Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety rivaling approved autologous products. CRBU trades near net cash value, implying the market assigns minimal value to its pipeline despite RMAT designation and promising Phase 1 results. Key risks include dilution, regulatory hurdles, and competition from in vivo CAR-T, but CRBU's CRISPR chRDNA editing and leadership provide strategic advantages.
Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is currently chief medical officer at Cellectis, the French biotechnology company focused on allogeneic CAR-T therapies, which engineer a patient's immune cells to target and destroy cancer.
Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution
Kyverna Therapeutics leads CAR-T therapy for autoimmune diseases, with KYV-101 showing unprecedented efficacy in SPS and MG registrational trials. KYTX's SPS trial achieved 81% clinically meaningful improvement and all secondary endpoints, positioning the company for a BLA filing in 1H 2026. With a $279M cash runway into 2028 and strong institutional backing, KYTX is de-risked from near-term dilution and aligns with top-tier biotech investors.
Avis Budget Group Stock Declines 21.8% Since Reporting Q4 Loss
CAR shares plunge 21.8% after Q4 loss of $6.53 per share and revenue miss as Americas sales fall. The 2026 EBITDA guidance ranges from $800M to $1B.
Avis Budget Group: A Broad Q4 Miss, A Big Impairment, And A Familiar Outcome
Avis Budget Group, Inc.'s Q4 2025 results were a broad miss: $2.66B revenue vs. $2.75B Street, FY25 revenue $11.65B, missing consensus for the third straight year. The big shock was profitability with FY25 adj. EBITDA is coming in at $748M vs. the original >$1B target (later cut to $900M–$1.0B), plus near-zero Q4 EBITDA vs. $157M guided. The international segment turned around in 2025 but still remains a minor revenue contributor (23% of Q4 revenue) vs. the Americas region.
What Analyst Projections for Key Metrics Reveal About Avis Budget (CAR) Q4 Earnings
Evaluate the expected performance of Avis Budget (CAR) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
